Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology
Biogen is acquiring Apellis Pharmaceuticals for approximately $5.6 billion in cash plus contingent value rights, gaining two FDA-approved immunology and rare disease medicines, EMPAVELI and SYFOVRE. The acquisition is expected to enhance Biogen's growth prospects by adding immediate revenues of $689 million in 2025 from Apellis' products, accelerat…